

## **CURRICULUM VITAE ET STUDIORUM**

**Aldo M. Roccaro**

### **EDUCATION**

- 1999: Doctor of Medicine, Summa cum Laude, University of Bari Medical School, Bari, Italy
- 2004: Specialist in Oncology, Summa cum Laude, University of Bari Medical School
- 2006-2008: Post-Doctoral Fellow, Research Associate in Medicine, Harvard Medical School, Boston, MA, USA
- 2008: PhD, Summa cum Laude, University of Bari Medical School, Bari, Italy
- 2008-2009: Instructor in Medicine, Harvard Medical School, Boston, MA, USA
- July 2010-Dec 2010: Research Scientist, Research Associate in Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
- Jan 2011-Jan 2016: Senior Research Scientist, Research Associate in Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
- January-October 2016: Physician Scientist, ASST Spedali Civili Brescia, Dept. of Medical Oncology, Brescia, BS, Italy
- October 2016-December 2017: Physician Scientist  
Dept. Clinical Research Development and Phase I Unit  
Medical Director Phase I Unit  
ASST Spedali Civili di Brescia, BS, Italy
- December 2017 – Present: Director Clinical Research Development and Phase I Unit  
Medical Director Phase I Unit  
ASST Spedali Civili di Brescia, BS, Italy

### **MEDICAL LICENSE**

- ✓ Ordine dei Medici, BAT #1289
- ✓ The Ministry of Education, Universities and Research  
License as Full Professor: Internal Medicine  
Hematology/Oncology  
Applied Biology  
Molecular Biology  
General and Clinical Pathology  
Clinical Biochemistry and Clinical Molecular Biology

### **PROFESSIONAL SOCIETES**

- 2000-2004: Member of the Italian Society of Internal Medicine
- 2007-present: American Society of Hematology (ASH)
- 2009-present European Hematology Association (EHA)
- 2014-present: AACR
- 2016-present: International Myeloma Society

### **HONORS AND PRIZES**

- 2016: "Fondazione Calabresi" award for translational research
- 2016: "Fondazione Chianello" award for cancer research
- 2015: "Campese Award for Leukemias", Italian Scientists and Scholars of North America Foundation, award given by Italian Ambassador, Claudio Bisogniero, Italian Embassy, Washington, DC, USA
- 2015: International Award for Cancer Research "De Luca", Accademia Nazionale dei Lincei, award given by the President of Italian Republic, Sergio Mattarella, Rome, Italy
- 2014: International Waldenstrom's Macroglobulinemia Foundation Award
- 2012: "V. Rizzo" Award, Accademia Nazionale dei Lincei, Rome, Italy
- 2012: The American Physician Scientist Association Award
- 2009: The Doctors Cancer Foundation Award

2009: Claudia Adams Barr Award, Harvard Medical School  
2006: Berlucchi Foundation for Cancer Research Award  
2003: Italian Association for Cancer Research (AIRC) Award

#### **EDITORIAL BOARD MEMBER**

Advances in Hematology; The Scientific World Journal; Translational Medicine Reports

#### **JOURNAL AD-HOC REVIEWER**

Blood; Cancer Research; Clinical Cancer Research; Leukemia; Haematologica; PLoS One; British Journal of Haematology; Clinical Experimental Medicine; Cancer; Journal of Cellular Biochemistry; Advances in Hematology; Clinical Lymphoma, Myeloma & Leukemia; Annals of Hematology; Expert Opinion On Biological Therapy; Histology and Histopathology; Clinical and Experimental Metastasis; Journal of Translational Medicine; Clinical Endocrinology; European Journal of Haematology; Expert Review of Hematology

#### **INTERNATIONAL GRANT REVIEWER**

Alberta Cancer Board, Alberta; Cancer Research UK Project Grant; Ministero della Salute, Roma; Hungarian Scientific Research Fund; Leukemia&Lymphoma Research; The Leukemia&Lymphoma Society; Czech Science Foundation; Austrian Science Research Fund

#### **FUNDED PROJECTS**

1. *Transcan2/EraNet/European Union*: "Single-cell immunophenotypic and transcriptomic profiling for minimally-invasive detection of early multiple myeloma"; Role: Principal Investigator; 2018-2021; € 432,259 (Partner together with France, German; Coordinator, Spain)
2. *Italian Association for Cancer Research (AIRC)*: "Dissecting clonal architecture in WM for therapeutic interventions"; Role: Principal Investigator; 2017-2020; € 210,000
3. *European Hematology Association (EHA)*: "Dissecting transcriptome aberrations within the bone marrow microenvironment, in Waldenström's Macroglobulinemia and the pre-malignant IgM MGUS stage"; Role: Principal Investigator; 2017-2019; €160,000.
4. *International Waldenstrom's Macroglobulinemia Foundation*: "Further genomic characterization of Waldenstrom's Macroglobulinemia: unveiling the role of the CXCR4 somatic mutation, a crucial regulator of pathogenesis and important target for therapy"; Role: Principal Investigator; 2013-2015; \$160,000
5. *Doctors Cancer Foundation*: "Targeting epigenetic modifications in multiple myeloma"; Role: Principal Investigator"; 2009-2010; \$50,000
6. *Claudia Adams Barr*: "MicroRNA profiling in Multiple Myeloma"; Role: Principal Investigator"; 2009-2011; \$240,000
7. *Bristol-Myers-Squibb*: "The effect of MDX-1338 on the cell-trafficking and homing of multiple myeloma cells into and out of the bone marrow"; Role: Principal Investigator; 2011-2012; \$25,000
8. *Health Research Board (HRB)*: "A translational research program in multiple myeloma"; Role: Principal Investigator; 2013-2014; €50,000
9. *NIH/NCI\_R01CA154648*: "The role of miRNA-15a and -16-1 in Multiple Myeloma"; Role: Senior Scientist; 2011-2016; \$2,168,750
10. *The Leukemia&Lymphoma Society*: "Targeting Hypoxic and Metabolic pathways in Multiple Myeloma"; Role: Senior Scientist; 2012-2015; \$504,045
11. *Multiple Myeloma Research Foundation*: "Chromatin, Writer, Reader and Erasers in Multiple Myeloma"; Role: Senior Scientist; 2013-2016 ;\$247,500

#### **INVITED SPEAKER AT INTERNATIONAL AND NATIONAL CONFERENCES (selected)**

Harvard Medical School, Boston, MA, USA; European Multiple Myeloma Academy; University of Pecs, Hungary; 77<sup>th</sup> Japanese Society of Hematology Meeting, Kanazawa, Japan; Multiple Myeloma and Related Malignancies (1st, 2nd, 3rd, 4th Editions); International Workshop on

Waldenström's Macroglobulinemia (3rd, 4th, 5th, 6th, 7th, 8th Editions); European Hematology Association 23rd Annual Meeting; European School of Hematology; Genomics Research, 2013, 2014 Editions; 3rd Epigenetic World Congress; RNAi and miRNA World Congress; 4th International microRNAs Europe Meeting; Joint Meeting Spanish Hematology and Hemotherapy Society/SHHS-Dana Farber; ASST Spedali Civili di Brescia; University of Bari Medical School; University of Brescia Medical School; University of Padua Medical School; University of Palermo Medical School; Italian Society of Experimental Hematology

#### **CITATION REPORT**

Publications in extenso: 154

H-Index: Scopus: 51

Google Scholar: 56

Citations: 6604

#### **PEER REVIEWED IN EXTENSO PUBLICATIONS (selected/154)**

1. Treon SP, Xu L, Guerrero ML, Jimenez C, Hunter ZR, Liu X, Demos M, Gustine J, Chan G, Munshi M, Tsakmaklis N, Chen JG, Kofides A, Sklaventis-Pistofidis R, Bustoros M, Keezer A, Meid K, Patterson CJ, Sacco A, **ROCCARO A**, Branagan AR, Yang G, Ghobrial IM, Castillo JJ. Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. *J Clin Oncol* 2020 Feb; : JCO1902314. **IF: 28.349**
2. Ronca R, Ghedini GC, Maccarinelli F, Sacco A, Locatelli SL, Foglio E, Taranto S, Grillo E, Matarazzo S, Castelli R, Paganini G, Desantis V, Cattane N, Cattaneo A, Mor M, Carlo-Stella C, Belotti A, Roccaro A, Presta M, Giacomini A. FGF trapping inhibits multiple myeloma growth through c-Myc degradation-induced mitochondrial oxidative stress. *Cancer Res.* 2020 Feb 24. pii: canres.2714.2019. **IF: 8.378**
3. Tsukamoto S, Løvendorf MB, Park J, Salem KZ, Reagan MR, Manier S, Zavidij O, Rahmat M, Huynh D, Takagi S, Kawano Y, Kokubun K, Thruue CA, Nagano K, Petri A, **ROCCARO AM**, Capelletti M, Baron R, Kauppinen S, Ghobrial IM. Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche. *Leukemia.* 2018;32:1739-1750. **IF: 9.944**
4. Kawano Y, Zavidij O, Park J, Moschetta M, Kokubun K, Mouhieddine TH, Manier S, Mishima Y, Murakami N, Bustoros M, Pistofidis RS, Reidy M, Shen YJ, Rahmat M, Lukyanchykov P, Karreci ES, Tsukamoto S, Shi J, Takagi S, Huynh D, Sacco A, Tai YT, Chesi M, Bergsagel PL, **ROCCARO AM**, Azzi J, Ghobrial IM. Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression. *J Clin Invest.* 2018;128:2487-2499. **IF: 12.282**
5. Takagi S, Tsukamoto S, Park J, Johnson KE, Kawano Y, Moschetta M, Liu CJ, Mishima Y, Kokubun K, Manier S, Salem KZ, Huynh D, Sacco A, Forward J, **ROCCARO AM**, Battinelli EM, Ghobrial IM. Platelets Enhance Multiple Myeloma Progression via IL-1 $\beta$  Upregulation. *Clin Cancer Res.* 2018;24:2430-2439. **IF: 8.911**
6. Kurdi AT, Glavey SV, Bezman NA, Jhatakia A, Guerriero JL, Manier S, Moschetta M, Mishima Y, **ROCCARO A**, Detappe A, Liu CJ, Sacco A, Huynh D, Tai YT, Robbins MD, Azzi J, Ghobrial IM. Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab. *Mol Cancer Ther.* 2018;17:1454-63. **IF: 5.365**
7. Sacco A, Kawano Y, Moschetta M, Zavidij O, Huynh D, Reagan M, Mishima Y, Manier S, Park J, Morgan E, Takagi S, Wong KK, Carrasco R, Ghobrial IM, **ROCCARO AM**. A novel in vivo model for studying conditional dual loss of BLIMP-1 and p53 in B-cells, leading to tumor transformation. *Am J Hematol.* 2017 May 5. doi: 10.1002/ajh.24778 **IF: 6.137**
8. Sacco A, Fenotti A, Affò L, Bazzana S, Russo D, Presta M, Malagola M, Anastasia A, Motta M, Patterson CJ, Rossi G, Imberti L, Treon SP, Ghobrial IM, **ROCCARO AM**. The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutic interventions. *Oncotarget.* 2017 Mar 11. doi: 10.18632/oncotarget.16130 **IF: 5.168**
9. Fulciniti M, Martinez-Lopez J, Senapedis W, Oliva S, Lakshmi Bandi R, Amodio N, Xu Y, Szalat R, Gulla A, Samur MK, **ROCCARO A**, Linares M, Cea M, Baloglu E, Argueta C, Landesman Y, Shacham S, Liu S, Schenone M, Wu SL, Karger B, Prabhala R, Anderson KC, Munshi NC. Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. *Blood.* 2017;129:2233-2245. **IF: 16.601**
10. Glavey SV, Naba A, Manier S, Clauser K, Tahri S, Park J, Reagan MR, Moschetta M, Mishima Y, Gambella M, Rocci A, Sacco A, O'Dwyer ME, Asara JM, Palumbo A, **ROCCARO AM**,\* Hynes RO,\*

- Ghobrial IM.\* (\*Co-LAST AUTHORS). Proteomic characterization of human multiple myeloma bone marrow extracellular matrix. *Leukemia*. 2017 Mar 27. doi: 10.1038/leu.2017.102. **IF: 9.944**
11. Kurdi AT, Glavey SV, Bezman NA, Jhatakia A, Guerriero JL, Manier S, Moschetta M, Mishima Y, **ROCCARO AM**, Detappe A, Liu CJ, Sacco A, Huynh D, Tai YT, Robbins MD, Azzi J, Ghobrial IM. Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab. *Mol Cancer Ther*. 2018;17:1454-1463. **IF: 5.365**
  12. Mishima Y, Paiva B, Shi J, Park J, Manier S, Takagi S, Massoud M, Perilla-Glen A, Aljawai Y, Huynh D, **ROCCARO AM**, Sacco A, Capelletti M, Detappe A, Alignani D, Anderson KC, Munshi NC, Prosper F, Lohr JG, Ha G, Freeman SS, Van Allen EM, Adalsteinsson VA, Michor F, San Miguel JF, Ghobrial IM. The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. *Cell Rep*. 2017;19:218-224. **IF: 8.24**
  13. Manier S, Liu CJ, Avet-Loiseau H, Park J, Shi J, Campigotto F, Salem KZ, Huynh D, Glavey SV, Rivotto B, Sacco A, **ROCCARO AM**, Bouyssou J, Minvielle S, Moreau P, Facon T, Leleu X, Weller E, Trippa L, Ghobrial IM. Prognostic role of circulating exosomal miRNAs in multiple myeloma. *Blood*. 2017 Feb 17. pii: blood-2016-09-742296. **IF: 16.601**
  14. **ROCCARO AM**,\* Sacco A, Shi J, Chiarini M, Perilla-Glen A, Manier S, Glavey S, Aljawai Y, Mishima Y, Kawano Y, Moschetta M, Correll M, Improgo MR, Brown JR, Imberti L, Rossi G, Castillo JJ, Treon SP, Freedman ML, Van Allen EM, Hide W, Hiller E, Rainville I, Ghobrial IM\*. Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia. (\*Co-last and Co-corresponding Authors). *Blood*. 2016;127:2598-606. **IF: 16.601**
  15. Manier S, Powers JT, Sacco A, Glavey SV, Huynh D, Reagan MR, Salem KZ, Moschetta M, Shi J, Mishima Y, Roche-Lestienne C, Leleu X, **ROCCARO AM**, Daley GQ, Ghobrial IM. The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma. *Leukemia*. 2016 Nov 11. doi: 10.1038/leu.2016.296. **IF: 9.944**
  16. Bertoli D, Re A, Chiarini M, Sottini A, Serana F, Giustini V, **ROCCARO AM**, Cattaneo C, Caimi L, Rossi G, Imberti L. B- and T-lymphocyte number and function in HIV+/HIV- lymphoma patients treated with high-dose chemotherapy and autologous bone marrow transplantation. *Sci Rep*. 2016 Dec 1;6:37995. doi: 10.1038/srep37995. **IF: 5.228**
  17. Moschetta M, Mishima Y, Kawano Y, Manier S, Paiva B, Palomera L, Aljawai Y, Calcinotto A, Unitt C, Sahin I, Sacco A, Glavey S, Shi J, Reagan MR, Prosper F, Bellone M, Chesi M, Bergsagel LP, Vacca A, **ROCCARO AM**,\* Ghobrial IM.\* (\*Co-last Senior Authors; Co-last Corresponding Authors). Targeting vasculogenesis to prevent progression in multiple myeloma. *Leukemia*. 2016 Feb 3. doi: 10.1038/leu.2016.3. **IF: 9.944**
  18. Sacco A,\* **ROCCARO AM**,\* (\*Co-first Author) Ma D, Shi J, Mishima Y, Moschetta M, Chiarini M, Munshi N, Handin RI, Ghobrial IM. Cancer Cell Dissemination and Homing to the Bone Marrow in a Zebrafish Model. *Cancer Res*. 2016 Jan 15;76(2):463-71. **IF: 9.13**
  19. **ROCCARO AM**, Mishima Y, Sacco A, Moschetta M, Shi J, Zhang Y, Reagan MR, Huynh D, Kawano Y, Sahin I, Chiarini M, Manier S, Cea M, Aljawai Y, Glavey S, Morgan E, Pan C, Michor F, Cardarelli P, Kuhne M, Ghobrial IM. CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal transition-like transcriptional activation. *Cell Reports*. 2015, pii:S2211-1247(15)00685-3. **IF: 8.24**
  20. Ghobrial IM, Redd R, Armand P, Boswell E, Chuma S, Huynh D, Sacco A, **ROCCARO A**, Noonan K, Leblebjian H, Warren D, Henrick P, Castillo JJ, Richardson PG, Matous J, Weller E, Treon SP. Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom Macroglobulinemia. *Leukemia*. 2015 Jul 3. doi: 10.1038/leu.2015.164. **IF: 9.944**
  21. Maiso P, Huynh D, Moschetta M, Sacco A, Aljawai Y, Mishima Y, Asara JM, **ROCCARO AM**, Kimmelman AC, Ghobrial IM. Metabolic signature identifies novel targets for drug resistance in Multiple Myeloma. *Cancer Res*. 2015 Mar 13. pii: canres.3400.2014. **IF: 9.13**
  22. Kawano Y, Moschetta M, Manier S, Glavey S, Gorgun G, **ROCCARO AM**, Anderson KC, Ghobrial IM. The bone marrow microenvironment in multiple myeloma. *Immunol Reviews*. 2015;263:160-172. **IF: 9.217**
  23. Bouyssou JMC, Ghobrial IM, **ROCCARO AM**. Targeting SDF-1 in multiple myeloma tumor microenvironment. *Cancer Letter*. 2015 Nov 30. pii:S0304-3835(15)00709-0. **IF: 6.491**
  24. Weinstock M, Aljawai Y, Morgan EA, Laubach J, Gannon M, **ROCCARO AM**, Varga C, Mitsiades CS, Paba-Prada C, Schlossman R, Munshi N, Anderson KC, Richardson PP, Weller E, Ghobrial IM. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. *Br J Haematol*. 2015 Apr 1. doi: 10.1111/bjh.13383. **IF: 5.206**
  25. Glavey SV, Huynh D, Reagan MR, Manier S, Moschetta M, Kawano Y, **ROCCARO AM**, Ghobrial IM, Joshi L, O'Dwyer ME. The cancer glycome: Carbohydrates as mediators of metastasis. *Blood Rev*. 2015 Jan 23. pii: S0268-960X(15)00005-3. doi: 10.1016/j.blre.2015.01.003. **IF: 6.6**

26. Banwait R, Aljawai Y, Cappuccio J, McDiarmid S, Morgan EA, Leblebjian H, **ROCCARO AM**, Laubach J, Castillo JJ, Paba-Prada C, Treon S, Redd R, Weller E, Ghobrial IM. Extramedullary Waldenstrom Macroglobulinemia. *Am J Hematol*, 2015;90(2):100-4. **IF: 6.137**
27. **ROCCARO AM**, Sacco A, Purschke WG, Moschetta M, Buchner K, Maasch C, Zboralski D, Zöllner S, Vonhoff S, Mishima Y, Maiso P, Reagan MR, Lonardi S, Ungari M, Facchetti F, Eulberg D, Kruschinski A, Vater A, Rossi G, Klussmann S, Ghobrial IM. SDF-1 Inhibition Targets the Bone Marrow Niche for Cancer Therapy. *Cell Reports*. 2014;9:118-28. **IF: 8.24**
28. Zhang Y, Moschetta M, Huynh D, Tai YT, Zhang Y, Zhang W, Mishima Y, Ring JE, Tam WF, Xu Q, Maiso P, Reagan M, Sahin I, Sacco A, Manier S, Aljawai Y, Glavey S, Munshi NC, Anderson KC, Pachter J, **ROCCARO AM,\*** Ghobrial IM.\* (Co-Last Senior Authors). Pyk2 promotes tumor progression in multiple myeloma. *Blood*. 2014; 124:2675-86. **IF: 16.601**
29. Reagan MR, Mishima Y, Glavey SV, Zhang Y, Manier S, Lu ZN, Memarzadeh M, Zhang Y, Sacco A, Aljawai Y, Shi J, Tai YT, Ready JE, Kaplan DL, **ROCCARO AM**, Ghobrial IM. Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. *Blood*, 2014;124:3250-3259. **IF: 16.601**
30. Azab AK, Sahin I, Moschetta M, Mishima Y, Burwick N, Zimmermann J, Romagnoli B, Patel K, Chevalier E, **ROCCARO AM**, Ghobrial IM. CXCR7-dependent angiogenic mononuclear cells trafficking regulates tumor progression in multiple myeloma. *Blood*, 2014;124:1905-1914. **IF: 16.601**
31. Glavey SV, Manier S, Natoni A, Sacco A, Moschetta M, Reagan MR, Murillo LS, Sahin I, Wu P, Mishima Y, Zhang Y, Zhang W, Zhang Y, Morgan G, Joshi L, **ROCCARO AM**, Ghobrial IM, O'Dwyer ME. The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma. *Blood*. 2014;124:1765-76. **IF: 16.601**
32. Zhang W, Wang YE, Zhang Y, Leleu X, Reagan M, Zhang Y, Mishima Y, Glavey S, Manier S, Sacco A, Jiang B, **ROCCARO AM,\*** Ghobrial IM.\* (\*Co-Last Senior Authors). Global epigenetic regulation of microRNAs in multiple myeloma. *PLoS One*. 2014;e110973. **IF: 4.09**
33. Sahin I, Azab F, Mishima Y, Moschetta M, Tsang B, Glavey SV, Manier S, Zhang Y, Sacco A, **ROCCARO AM**, Azab AK, Ghobrial IM. Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib. *Am J Hematol*. 2014;89:1030-6. **IF: 6.137**
34. Swami A, Reagan MR, Basto P, Mishima Y, Kamaly N, Glavey S, Zhang S, Moschetta M, Seevaratnam D, Zhang Y, Liu J, Memarzadeh M, Wu J, Manier S, Shi J, Bertrand N, Lu ZN, Nagano K, Baron R, Sacco A, **ROCCARO AM**, Farokhzad OC, Ghobrial IM. Engineered nanomedicine for myeloma and bone microenvironment targeting. *Proc Natl Acad Sci U S A*, 2014;111:10287-10292. **IF: 9.504**
35. **ROCCARO AM**, Sacco A, Jimenez C, Maiso P, Moschetta M, Mishima Y, Aljawai Y, Sahin I, Kuhne M, Cardarelli P, Cohen L, San Miguel JF, Garcia-Sanz R, Ghobrial IM. C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. *Blood*. 2014;123:4120-4131. **IF: 16.601**
36. Moschetta M, Mishima Y, Sahin I, Manier S, Glavey S, Vacca A,, **ROCCARO AM**, Ghobrial IM. Role of endothelial progenitor cells in cancer progression. *Biochim Biophys Acta*. 2014 Apr 4. pii: S0304-419X(14)00026-2. **IF: 8.901**
37. Bouyssou JM, Manier S, Huynh D, Issa S, **ROCCARO AM**, Ghobrial IM. Regulation of microRNAs in cancer metastasis. *Biochim Biophys Acta*. 2014 Feb 22;1845(2):255-265. **IF: 8.901**
38. Sahin I, Moschetta M, Mishima Y, Glavey SV, Tsang B, Azab F, Manier S, Zhang Y, Maiso P, Sacco A, Azab AK, **ROCCARO AM**, Ghobrial IM. Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination. *Blood Cancer J*. 2014 Apr 25;4:e204. doi: 10.1038/bcj.2014.24. **IF: 8.125**
39. Moschetta M, Basile A, Ferrucci A, Frassanito MA, Rao L, Ria R, Solimando AG, Giuliani N, Boccarelli A, Fumarola F, Coluccia M, Rossini B, Ruggieri S, Nico B, Maiorano E, Ribatti D, **ROCCARO AM**, Vacca A. Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma. *Clin Cancer Res*. 2013;19:4371-4382. **IF: 8.911**
40. **ROCCARO AM**, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, Azab F, Flores LM, Campigotto F, Weller E, Anderson KC, Scadden DT, Ghobrial IM. Bone marrow mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. *J Clin Invest*, 2013;123:4:15421554. **IF: 12.282**
41. **ROCCARO AM**, Sacco A, Jia X, Banwait R, Maiso P, Azab F, Flores L, Manier S, Azab AK, Ghobrial IM. Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom's Macroglobulinemia. *Clin Cancer Res*, 2012;18:6609-6622. **IF: 8.911**
42. Zhang Y, **ROCCARO AM**, Rombaoa C, Flores L, Obad S, Fernandes SM, Sacco A, Liu Y, Ngo H, Quang P, Azab AK, Azab F, Maiso P, Reagan M, Brown JR, Thai TH, Kauppinen S, Ghobrial IM. LNA-mediated anti-microRNA-155 silencing in low grade B- cell lymphomas. *Blood* 2012;120:1678-1686. **IF: 16.601**

43. Blotta S, Jakubikova J, Calimeri T, **ROCCARO AM**, Amodio N, Azab AK, Foresta U, Mitsiades CS, Rossi M, Todoerti K, Molica S, Morabito F, Neri A, Tagliaferri P, Tassone P, Anderson KC, Munshi NC. Canonical and non canonical Hedgehog pathway in the pathogenesis of Multiple Myeloma. (CB-17 SCID mice). *Blood* 2012;120:5002-5013. **IF: 16.601**
44. Cea M, Cagnetta A, Fulciniti M, Tai YT, Hideshima T, Chauhan D, **Roccaro AM**, Sacco A, Calimeri T, Cottini F, Jakubikova J, Kong SY, Patrone F, Nencioni A, Gobbi M, Richardson P, Munshi N, Anderson KC. Targeting NAD+ Salvage Pathway Induces Autophagy in Multiple Myeloma Cells via mTORC1 and Extracellular Signal-Regulated Kinase (ERK1/2) Inhibition. *Blood*. 2012;120:3519-29. **IF: 16.601**
45. Azab AK, Hu J, Quang P, Azab F, Pitsillides C, Awwad R, Thompson B, Maiso P, Sun JD, Hart CP, **ROCCARO AM**, Sacco A, Ngo HT, Lin CP, Kung AL, Carrasco RD, Vanderkerken K, Ghobrial IM. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. *Blood*. 2012;119:5782-94. **IF: 16.601**
46. Azab AK, Quang P, Azab F, Pitsillides C, Thompson B, Chonghaile T, Patton JT, Maiso P, Monroe V, Sacco A, Ngo HT, Flores LM, Lin CP, Magnani JL, Kung AL, Letai A, Carrasco R, **ROCCARO AM**, Ghobrial IM. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. *Blood*. 2012;119:1468-78. **IF: 16.601**
47. Azab F, Azab AK, Maiso P, Calimeri T, Flores L, Liu Y, Quang P, **ROCCARO AM**, Sacco A, Ngo HT, Zhang Y, Morgan BL, Carrasco RD, Ghobrial IM. Eph-B2/ephrin-B2 interaction plays a major role in the adhesion and proliferation of Waldenstrom's macroglobulinemia. *Clin Cancer Res*. 2012;18:91-104. **IF: 8.9119**
48. Maiso P, Liu Y, Morgan B, Azab AK, Ren P, Martin MB, Zhang Y, Liu Y, Sacco A, Ngo H, Azab F, Quang P, Rodig SJ, Lin CP, **ROCCARO AM**, Rommel C, Ghobrial IM. Defining the role of TORC1/2 in multiple myeloma. *Blood*. 2011;118:6860-70. **IF: 16.601**
49. Sacco A, Aujay M, Morgan B, Azab AK, Maiso P, Liu Y, Zhang Y, Azab F, Ngo HT, Issa GC, Quang P, **ROCCARO AM\***, Ghobrial IM\* (\*Co-Last Authors; \*Corresponding Author). Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to anti-tumor activity in Waldenstrom's macroglobulinemia. *Clin Cancer Res*, 2011;17:1753-64. **IF: 8.911**
50. Ghobrial IM, Weller E, Vij R, Munshi NC, Banwait R, Bagshaw M, Schlossman R, Leduc R, Chuma S, Kunsman J, Laubach J, Jakubowiak AJ, Maiso P, **ROCCARO AM**, Armand P, Dollard A, Warren D, Harris B, Poon T, Sam A, Rodig S, Anderson KC, Richardson PG. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. *The Lancet Oncology* 2011; 12:263-72. **IF: 35.386**
51. Azab AK, Azab F, Quang P, Maiso P, Sacco A, Ngo HT, Liu Y, Zhang Y, Morgan BL, **ROCCARO AM**, Ghobrial IM. FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation. *Clin Cancer Res*. 2011;17:4389-99. **IF: 8.911**
52. Sacco A, Ghobrial IM, **ROCCARO AM**. Anti-Angiogenic Therapies in the Treatment of Waldenstrom's Macroglobulinemia. *Current cancer drug targets*. 2011; 11:1025-9. **IF: 2.626**
53. Calvo KR, Landgren O, **ROCCARO AM**, Ghobrial IM. Role of microRNAs from MGUS to multiple myeloma. *Semin Oncol*,2011;48:39-45. **IF: 4.942**
54. **ROCCARO AM**, Sacco A, Jia X, Azab AK, Maiso P, Ngo HT, Azab F, Runnels J, Quang P, Ghobrial IM. microRNA-dependent modulation of histone acetylation in Waldenstrom Macroglobulinemia. *Blood* 2010;116:1506-14. **IF: 16.601**
55. **ROCCARO AM**, Sacco A, Aujay M, Ngo HT, Azab AK, Azab F, Quang P, Maiso P, Runnels J, Anderson KC, Demo S, Ghobrial IM. Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom Macroglobulinemia. *Blood*. 2010;115:4051-60. **IF: 16.601**
56. **ROCCARO AM**, Sacco A, Husu EN, Pitsillides C, Vesole S, Azab AK, Azab F, Melhem M, Ngo HT, Quang P, Maiso P, Runnels J, Liang MC, Wong KK, Lin C, Ghobrial IM. Dual targeting of the PI3K/Akt/mTOR pathway as an anti-tumor strategy in Waldenstrom's Macroglobulinemia. *Blood*, 2010;115:559-69. **IF: 16.601**
57. Sacco A, **ROCCARO A**, Ghobrial IM. Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia. *Oncotarget*. 2010;1:578-82. **IF: 5.168**
58. Sacco A, Ghobrial IM, **ROCCARO AM**. Epigenetics in Waldenström's macroglobulinemia. *Epigenomics*, 2010;2:691-6. **IF: 4.979**
59. Sacco A, Issa GC, Zhang Y, Liu Y, Maiso P, Ghobrial IM, **ROCCARO AM**. Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biology. *J Hematol Oncol*. 2010 Oct 7;3:38. **IF: 8.731**

60. **ROCCARO AM**, Sacco A, Thompson B, Leleu X, Azab AK, Azab F, Runnels J, Jia X, Ngo HT, Melhem MR, Lin CP, Ribatti D, Rollins BJ, Witzig TE, Anderson KC, Ghobrial IM. microRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. *Blood*. 2009; 113:6669-80. **IF: 16.601**
61. **ROCCARO AM**, Sacco A, Chen C, Runnels J, Leleu X, Azab F, Azab AK, Jia X, Ngo HT, Melhem MR, Burwick N, Varticovski L, Novina CD, Rollins BJ, Anderson KC, Ghobrial IM. microRNA expression in the biology, prognosis and therapy of Waldenstrom Macroglobulinemia. *Blood*, 2009;113:4391-402. **IF: 16.601**
62. Ghobrial,\* **ROCCARO A,\*** (Co-First Authors) Hong F, Weller E, Rubin N, Leduc R, Rourke M, Chuma S, Sacco A, Jia X, Azab F, Azab AK, Rodig S, Warren D, Harris B, Varticovski L, Sportelli P, Leleu X, Anderson KC, Richardson PG.\*CO-FIRST AUTHOR Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. *Clin Cancer Res*. 2010;16:1033-41. **IF: 8.911**
63. Azab AK, Azab F, Blotta S, Pitsillides CM, Thompson B, Runnels JM, **ROCCARO AM**, Ngo HT, Melhem MR, Sacco A, Jia X, Anderson KC, Lin CP, Rollins BJ, Ghobrial IM. Rho-A and Rac-1 GTPases play major and differential roles in SDF1-induced cell adhesion and chemotaxis in multiple myeloma. *Blood*. 2009; 114:619-29. **IF: 16.601**
64. Leleu X, Soumerai J, Roccaro A, Hatjiharissi E, Hunter ZR, Manning R, Ciccarelli BT, Sacco A, Ioakimidis L, Adamia S, Moreau AS, Patterson CJ, Ghobrial IM, Treon SP. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. *J Clin Oncol*. 2009;27:250-5. **IF: 28.349**
65. Ngo HT, Azab AK, Farag M, Jia X, Melhem MM, Runnels J, **ROCCARO AM**, Azab F, Sacco A, Leleu X, Anderson KC, Ghobrial IM. Src Tyrosine Kinase Regulates Adhesion and Chemotaxis in Waldenstrom Macroglobulinemia. *Clin Cancer Res*. 2009; 15:6035-41. **IF: 8.911**
66. Leleu X, Hunter ZR, Xu L, **ROCCARO AM**, Moreau AS, Santos DD, Hatjiharissi E, Bakthavachalam V, Adamia S, Ho AW, Soumerai J, Patterson CJ, Manning RJ, Hamilton S, Verselis S, Fox E, Carrasco R, Ghobrial IM, Treon SP. Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia. *Br J Haematol*. 2009;145:59-63. **IF: 5.206**
67. Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X, Jia X, Wright R, Ospina B, Carlson AL, Alt C, Burwick N, **ROCCARO AM**, Ngo HT, Farag M, Melhem MR, Sacco A, Munshi NC, Hideshima T, Rollins BJ, Anderson KC, Kung AL, Lin CP, Ghobrial IM. The CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. *Blood*, 2009; 113:4341-51. **IF: 16.601**
68. Leleu X, Xu L, Jia X, Sacco A, Farag M, Hunter ZR, Moreau AS, Ngo HT, Hatjiharissi E, Ho AW, Santos DD, Adamia S, O'Connor K, Ciccarelli B, Soumerai J, Manning RJ, Patterson CJ, **ROCCARO AM**, Ghobrial IM, Treon SP. Endoplasmic reticulum stress is a target for therapy in Waldenstrom Macroglobulinemia. *Blood*, 2009;113:626-34. **IF: 16.601**
69. **ROCCARO AM**, Leleu X, Sacco A, Jia X, Melhem M, Moreau AS, Ngo HT, Runnels J, Azab A, Azab F, Burwick N, Farag M, Treon SP, Palladino MA, Hideshima T, Chauhan D, Anderson KC, Ghobrial IM. Dual targeting of the proteasome regulates survival and homing in Waldenstrom's Macroglobulinemia. *Blood*, 2008;111:4752-63. **IF: 16.601**
70. **ROCCARO AM**, Leleu X, Sacco A, Moreau AS, Hatjiharissi E, Jia X, Xu L, Ciccarelli B, Patterson CJ, Ngo HT, Russo D, Vacca A, Dammacco F, Anderson KC, Ghobrial IM, Treon SP. Resveratrol exerts anti-proliferative activity and induces apoptosis in Waldenstrom's Macroglobulinemia. *Clin Cancer Res*, 2008;14:1849-1858. **IF: 8.911**
71. Moreau AS, Jia X, Patterson CJ, **ROCCARO AM**, Xu L, Sacco A, O'Connor K, Soumerai J, Ngo HT, Hatjiharissi E, Hunter ZR, Ciccarelli B, Manning R, Ghobrial IM, Leleu X, Treon SP. The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. *Br J Haematol*. 2008;142:775-85. **IF: 5.206**
72. Leleu X, Eeckhoutte J, Jia X, **ROCCARO AM**, Moreau AS, Farag M, Sacco A, Ngo HT, Runnels J, Melhem MR, Burwick N, Azab A, Azab F, Hunter Z, Hatjiharissi E, Carrasco DR, Treon SP, Witzig TE, Hideshima T, Brown M, Anderson KC, Ghobrial IM. Targeting NF-κB in Waldenstrom macroglobulinemia. *Blood*, 2008;111:5068-5077. **IF: 16.601**
73. Ngo HT, Leleu X, Lee J, Jia X, Melhem M, Runnels J, Moreau AS, Burwick N, Azab AK, **ROCCARO AM**, Azab F, Sacco A, Farag M, Sackstein R, Ghobrial IM. SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom Macroglobulinemia. *Blood*, 2008;112:150-58. **IF: 16.601**
74. Huston A, Leleu X, Jia X, Moreau AS, Ngo HT, Runnels J, Anderson J, Alsayed Y, **ROCCARO AM**, Vallet S, Hatjiharissi E, Tai YT, Sportelli P, Munshi N, Richardson P, Hideshima T, Roodman DG, Anderson KC, Ghobrial IM. Targeting Akt and HSP90 produces synergistic Multiple Myeloma cell cytotoxicity in the bone marrow microenvironment. *Clin Cancer Res*, 2008;14:865-874. **IF: 8.911**

75. Leleu X, **ROCCARO AM**, Moreau AS, Dupire S, Robu D, Gay J, Hatjiharissi E, Burwik N, Ghobrial IM. Waldenstrom macroglobulinemia. *Cancer Lett*, 2008;18:95-107. **IF: 6.491**
76. Leleu X, Jia X, Runnels J, Ngo HT, Moreau AS, Farag M, Spencer JA, Pitsillides CM, Hatjiharissi E, **ROCCARO AM**, O'Sullivan G, McMillin DW, Moreno D, Kiziltepe T, Carrasco R, Treon SP, Hideshima T, Anderson KC, Lin CP, Ghobrial IM. The Akt pathway regulates survival and homing in Waldenstrom Macroglobulinemia. *Blood*, 2007;110:4417-26. **IF: 16.601**
77. Ribatti D, Nico B, Crivellato E, **ROCCARO AM**, Vacca A.. The history of the angiogenic switch concept. *Leukemia*. 2007;21:44-52. **IF: 9.944**
78. **ROCCARO AM**, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H, Shiraishi N, Ribatti D, Nico B, Vacca A, Dammacco F, Richardson PG, Anderson KC. Bortezomib mediates anti-angiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. *Cancer Res*. 2006;66:184-91. **IF: 9.130**
79. Yasui H, Hideshima T, Raje N, **ROCCARO AM**, Shiraishi N, Kumar S, Hamasaki M, Ishitsuka K, Tai YT, Podar K, Catley L, Mitsiades CS, Richardson PG, Albert R, Brinkmann V, Chauhan D, Anderson KC. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. *Cancer Res*. 2005;65:7478-7484. **IF: 9.130**
80. Ishitsuka K, Hideshima T, Hamasaki M, Raje N, Kumar S, Podar K, Le Gouill S, Shiraishi N, Yasui H, **ROCCARO AM**, Tai YZ, Chauhan D, Fram R, Tamura K, Jain J, Anderson KC. Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. *Oncogene*, 2005;24:5888-589. **IF: 6.854**
81. Ishitsuka K, Hideshima T, Hamasaki M, Raje N, Kumar S, Hideshima H, Shiraishi N, Yasui H, **ROCCARO AM**, Richardson P, Podar K, Le Gouill S, Chauhan D, Tamura K, Arbiser J, Anderson KC. Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and independent apoptosis. *Blood*. 2005;106:1794-1800. **IF: 16.601**
82. Raje N, Kumar S, Hideshima T, **ROCCARO AM**, Ishitsuka K, Yasui H, Shiraishi N, Chauhan D, Munshi NC, Green SR, Anderson KC. Seliciclib (CYC202 or R-Roscovitine), a small molecule cyclin dependent kinase inhibitor, mediates activity via downregulation of Mcl-1 in multiple myeloma. *Blood*. 2005;106:1042-1047. **IF: 16.601**
83. Kumar S, Raje N, Hideshima T, Ishitsuka K, **ROCCARO AM**, Shiraishi N, Hamasaki M, Yasui H, Munshi NC, Richardson P, Figg WD, Anderson KC. Antimyeloma activity of two novel N-substituted and tetrafluorinated thalidomide analogs. *Leukemia*. 2005;19:1253-1261. **IF: 9.944**
84. Yasui H, Hideshima T, Hamasaki M, **ROCCARO AM**, Shiraishi N, Kumar S, Tassone P, Ishitsuka K, Raje N, Tai YT, Podar K, Chauhan D, Leoni LM, Kanekal S, Elliott G, Munshi NC, Anderson KC. SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. *Blood*. 2005;106:706-712. **IF: 16.601**
85. Ribatti D, Molica S, Vacca A, Nico B, Crivellato E, **ROCCARO AM**, Dammacco F. Tryptase-positive mast cells correlate positively with bone marrow angiogenesis in B-cell chronic lymphocytic leukemia. *Leukemia*, 2003;17:1428-1430. **IF: 9.944**
86. Ria R, **ROCCARO AM**, Merchionne F, Vacca A, Dammacco F, Ribatti D. Vascular endothelial growth factor and its receptors in multiple myeloma. *Leukemia*, 2003;17:1961-1966. **IF: 9.944**
87. Molica S, Vacca A, Ribatti D, Cuneo A, Cavazzini F, Levato D, Vitelli G, Tucci L, **ROCCARO AM**, Dammacco F. Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leucemia. *Blood*, 2002;100:3344-3351. **IF: 16.601**

#### **COMMENTARIES RELATED TO PUBLISHED MANUSCRIPTS**

1. J.D. LATHIA. EDITOR'S CHOICE. Protecting the fortress: preventing metastasis by neutralizing niche homing. *Sci Transl Med* 8 October 2014: Vol. 6, Issue 257, p. 257ec172. Commentary related to Roccaro et al. *Cell Reports*. 2014;9:118-28.
2. Y.A. EFEBERA. It is time to move forward with Waldenstrom! *Blood* 2014;123:4007-4008. Commentary related to Roccaro et al. *Blood*. 2014;123:4120-31.
3. L.H. BOISE. Aiming at WM with both barrels blocked. *Blood* 2010;115:4007-4008. Commentary related to Roccaro et al. *Blood*. 2010;115:4051-60.
4. A. VACCA, F. DAMMACCO. MicroRNAs to know in Waldenstrom Macroglobulinemia. *Blood* 2009;113:4133-4134. Commentary related to *Blood*, 2009;113:4391-402.

#### **BOOK CHAPTERS**

1. SACCO A, MOSCHETTA M, MANIER S, ROSSI G, GHOBRIAL IM, **ROCCARO AM**. Molecular pathways in growth and survival: Epigenomics. In: Waldenstrom's Macroglobulinemia. 2016. Springer. (Editors: V. Leblond, S. Treon, M. Dimopoulos).



2. KASTRITIS E, **ROCCARO A**, MIGOU M, GHOBRIAL I. The Bone Marrow Microenvironment and Tumor Cells Interactions in Waldenström's Macroglobulinemia. In: Waldenström's Macroglobulinemia. 2016 (Editors: V. Leblond, S. Treon, M. Dimopoulos). Springer.
3. **AM ROCCARO**, G BIANCHI, IM GHOBRIAL, KC ANDERSON. Multiple Myeloma. Hematology-Oncology Therapy Guidelines. NCI. 2014; McGraw-Hill. Book Chapter.
4. **ROCCARO AM**, GHOBRIAL IM. microRNA aberrations and their role in supporting hematologic malignancies. Editorial in MicroRNA, 2013;Vol.2; n.3. Bentham Science Publishers.
5. GLAVEY S, MANIER S, SACCO A, ROSSI G, GHOBRIAL IM, **ROCCARO AM**. The role of miRNAs in plasma cells dyscrasias. MicroRNA, 2013; 2014;2(3):165-73. Bentham Science Publishers.
6. IM GHOBRIAL, **AM ROCCARO**, X LELEU. Bortezomib in Waldenström's Macroglobulinemia. In: Bortezomib in the treatment of multiple myeloma. Editors: Drs. IM Ghobrial, PG Richardson, KC Anderson. Springer. 2011.
7. **AM ROCCARO**, A VACCA, G ROSSI, IM GHOBRIAL. The multiple myeloma bone marrow microenvironment. Editors: Drs. K. Podar, KC Anderson. 2011. Bentham Science Publishers. E-Book.
8. IM GHOBRIAL, X LELEU, A **ROCCARO**, N BURWICK, SP TREON. Advances in the understanding and treatment of Waldenström Macroglobulinemia. 2010. Multiple Myeloma State of the Art Second Edition. Editors: Drs. PG Richardson, KC Anderson. Remedica
9. **AM ROCCARO**, IM GHOBRIAL. Novel Antiangiogenic Molecules in Multiple Myeloma. Recent Advances in Angiogenesis and Anti-angiogenesis. Editor: Dr. D. Ribatti. 2009;127-133. Bentham Publishers.
10. VACCA A., **A.M. ROCCARO**, D. RIBATTI, C. SCAVELLI, F. DAMMACCO (2003). Angiogenesis and anti-angiogenesis. Editor: F. Morabito. Il Mieloma Multiplo. p. 311-329, PAVIA: Selecta Medica.
11. VACCA A., ROSSINI B, **ROCCARO A**, DAMMACCO F (2005). Genomic alterations of plasma cells and microenvironment. In: SOCIETA' EDITRICE ESCULAPIO. Atti del Corso Nazionale di Aggiornamento in Ematologia Clinica, Bologna, 2005. p. 181-186, BOLOGNA: Società Editrice Esculapio.
12. VACCA A, **ROCCARO AM**, SCAVELLI C, RIBATTI D, DAMMACCO F. Anti-angiogenic effects of chemotherapeutics. In: "Seminars in Oncology. Angiogenesis and Neoplasias: clinical relevance and therapeutical implications". 2002. Editor: Molica.
13. RIBATTI D, **ROCCARO AM**, DE FALCO G, VACCA A. Methodologies for studying angiogenesis. In: "Seminars in Oncology. Angiogenesis and Neoplasias: clinical relevance and therapeutical implications". Editor: Molica.

#### **PATENT**

- Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenström's Macroglobulinemia. Patent number:US8394816 B2;
- Compositions and methods for diagnosis, prognosis and treatment of hematological malignancies. Patent number:WO2014071205 A1

#### **OTHER**

- Translator from English to Italian of the Atlas "Netter, Clinical Anatomy"
- EHA Abstract Reviewer (21<sup>st</sup> EHA Conference, Copenhagen, Denmark, 2016)
- ASH Abstract Reviewer (56<sup>th</sup> ASH meeting, San Francisco, CA, USA, 2014)
- ASH Education Program Real Time Peer Reviewer (56<sup>th</sup> ASH meeting, San Francisco, CA, USA, 2014)
- ASH Abstract Reviewer (51<sup>th</sup> ASH Meeting, New Orleans, LA, USA, 2009)

#### **TEACHING AND TRAINING AT EUROPEAN AND AMERICAN UNIVERSITIES**

- 2000-2004: Medical School Courses; Internal Medicine; Univ. Bari Medical School
- 2004: Oncology Fellows Teaching Conferences; Multiple Myeloma; Angiogenesis - Anti-angiogenetic drugs; Dept. of Internal Medicine and Clinical Oncology; Univ. of Bari
- 2006: Postdoctoral fellows, research technicians, teaching conference; Role of angiogenesis in MM; Dept. of Biotechnologies; Univ. of Brescia Medical School
- 2006-Dec2009; June 2010-2016: Advisor in Lab, Dana-Farber Cancer Institute, Boston, MA, USA, for post-doctoral fellows, research technicians, summer students

- 2007: Hematologists, Hematology fellows teaching conference; Role of anti-angiogenetic drugs in multiple myeloma; Dept of Hematology; Univ. of Brescia Medical School, Brescia
- 2007: Primary Care Physicians; Anti-angiogenetic drugs in myeloma. Univ. of Brescia
- 2008: Medical School Students, Hem/Oncology Residents; Univ. Brescia Med School
- Jan 2016-present: Advisor in Lab, ASST Spedali Civili, CREA Laboratory, Brescia, for post-doctoral fellows, research technicians, summer students.

Il sottoscritto, acquisita l'informativa di cui all'art. 13 Decreto Legislativo 196/03 e art. 13 GDPR 679/16 con l'invio del proprio CV presta il proprio consenso, ai sensi degli art. 23 e 26 del decreto stesso, al trattamento dei dati personali, anche sensibili, che ha ritenuto opportuno indicare nel CV.

Brescia, 13/03/2020

Aldo M. Roccaro